Drug Discovery and Development: Technology in Transition
This title is directed primarily toward health care professionals outside the United States. An ideal introduction to the pharmaceutical industry, this book describes the process of bringing a new drug to the marketplace. It explains why, although thousands of compounds show initial promise, only a small handful will be developed for human clinical trials and perhaps only one will become an approved drug. Describing the huge complexities involved, it shows how new molecular understanding and techniques can make the process more targeted and successful.
What people are saying - Write a review
We haven't found any reviews in the usual places.
introduction 221 22 Drug discovery and development facts
The nature of disease and the purpose of Choosing the project
13 other sections not shown
acid activity analysis animal models antibodies application approach assays assessment binding bioinformatics biological biopharmaceuticals biotechnology cancer cell-based cells Chapter chemical clinical trials combinatorial chemistry databases defined disease DMPK dose drug candidate drug development drug discovery drug discovery project drug metabolism drug targets effects efficacy enzymes evaluation example factors fluorescence function gene expression gene therapy genetic genome groups hepatocytes high-throughput screening hormone human identified imatinib inhibitors interactions involved Journal kinase lead identification lead optimization libraries ligands marketing measured Medicinal Chemistry metabolites Microarray molecular molecules mRNA natural products oral organisms Paclitaxel patients peptides pharmaceutical companies pharmaceutical industry pharmacokinetic pharmacological pharmacophore Phase phenotype physiological potential preclinical predict profiling properties protein receptor recombinant relevant safety scientific selected sequence silico specific strategy structure studies synthesis synthetic therapeutic tion tissues toxicity toxicology transgenic typically vaccines validity vitro vivo